Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilars Pathway Dilemma: When Should Sponsors Pick (k) Before (a)?

Executive Summary

Extrapolation and interchangeability appear to be the linchpins for biosimilar sponsors mulling whether to send applications to the emerging 351(k) pathway or the traditional novel biologics approval system.

You may also be interested in...



Sandoz Pushing FDA To Make Biosimilar Interchangeability Decisions

Absent guidance, the company says it is submitting proposals for trial designs it believes could demonstrate biosimilar interchangeability.

Where Are The Biosimilars?

An abbreviated pathway for follow-on biologics was one of the biggest issues for biotech investors in the legislative debate over health care reform. Two years after enactment, FDA is still waiting for the first application.

Biosimilar Meeting Requests Increase, But FDA Cancels Some For Lack Of Data

Some early meeting requests from potential biosimilar sponsors were not held because they did not include the necessary information for FDA to give development advice.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel